Latest:
Dr Sparano on Advances in Breast Cancer Screening, Treatment, and Drug Development
Joseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Joseph Uberti, MD, PhD
Latest:
Dr. Uberti on Transplant in Myelodysplastic Syndrome
Joseph Uberti, MD, PhD, division head, BMT, Leukemia & Lymphoma, professor of medicine, Department of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University, discusses the use of transplant in myelodysplastic syndrome (MDS).
Josephine Feliciano, MD
Latest:
The Importance of Mentorship for Oncology and Hematology Fellows
What is mentorship? The term "mentor" originates with the mythological character Mentor, with whom Odysseus entrusted his son, Telemachus. Mentor was responsible for educating and instilling values in Telemachus when Odysseus departed for the Trojan War.
Josephine Lai, PharmD, MBA, BCPS, & Ted Wun, MD
Latest:
Oncology Pharmacy Program Ensures Medication Adherence
The rise of oral anticancer agents is revolutionizing cancer treatment for both patients and cancer care providers. Patients can take their medications in the comfort of their own homes without the need for needles, long stints in infusion chairs or intensive nursing oversight.
Joshua Brody, MD, of Mount Sinai Hospital
Latest:
Catching Up on the Latest Data in CLL and Lymphoma With Drs Emmons, Brody, and Pinilla
Robert Emmons, MD, FACP, Joshua Brody, MD, and Javier Pinilla, MD, PhD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in chronic lymphocytic leukemia and lymphoma presented during the 2025 ASH Annual Meeting & Exposition.
Joshua D. Waltonen, MD, Christopher A. Sullivan, MD
Latest:
Transoral Surgery for Oropharyngeal Squamous Cell Carcinoma
The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has been steadily increasing over the last few decades, mostly due to HPV, which is now associated with the majority of newly diagnosed cases of OPSCC.
Joshua K. Sabari, MD
Joshua K. Sabari, MD, is an associate professor in the Department of Medicine at New York University (NYU) Grossman School of Medicine. He is also medical director, ofThoracic Medical Oncology at NYU Langone Health’s Perlmutter Cancer Center.
Latest:
Looking Forward: Combination Therapy for HER2 Mutation mNSCLC
Panelists discuss how combination therapies represent the future of HER2 mutation treatment, drawing parallels to successful EGFR combination strategies, with particular interest in anti-VEGF agents and potentially anti-PD-1/PD-L1 therapies, while noting that zongertinib’s favorable tolerability profile makes it an ideal candidate for combination approaches compared with more toxic agents like trastuzumab deruxtecan or sevabertinib, though current trial designs should incorporate 3-armed studies to evaluate up-front combination strategies rather than sequential monotherapy comparisons.
Joshua M. Bauml, MD, Perelman School of Medicine
Latest:
Current and Future Use of MET Inhibitors in NSCLC
Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.